HRAS and cancer: The oncogenic Ras isoforms, KRas, HRas and NRas, whose mutations have been found in more than 30% of human cancers, as well as overexpression of growth factors and mutations of their receptors in human cancer, all lead to the activation of this pathway [11,12,16].